Literature DB >> 12559500

Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.

Sandra Vukusic1, Christian Confavreux.   

Abstract

Predicting clinical outcome is one of the major and most interesting issues in MS patients. If the global evolution of disability (usually chosen levels on the Kurtzke's Disability Status Scale) has been widely studied, much less is known about the progression of disability during the secondary progressive phase of the disease. It is usually said that there is a poorer prognosis once patients enter a progressive phase, whether from onset (like in primary progressive MS) or after an initial relapsing-remitting phase. The secondary progressive phase of multiple sclerosis (MS) is the one most often associated with the development of severe and irreversible disability. Despite this fact, there is a lot of information about the initial relapsing-remitting phase in the literature, but much less about the secondary progressive one. We review here information available from the literature and from the Lyon MS database about this secondary progressive phase.

Entities:  

Mesh:

Year:  2003        PMID: 12559500     DOI: 10.1016/s0022-510x(02)00426-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  27 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

Review 2.  Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Authors:  Axel Petzold
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 3.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

4.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

Review 5.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 6.  Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.

Authors:  Jin Nakahara; Michiko Maeda; Sadakazu Aiso; Norihiro Suzuki
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

7.  Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Authors:  Elina Misicka; Corriene Sept; Farren B S Briggs
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

8.  Decreased NAA in gray matter is correlated with decreased availability of acetate in white matter in postmortem multiple sclerosis cortex.

Authors:  S Li; R Clements; M Sulak; R Gregory; E Freeman; J McDonough
Journal:  Neurochem Res       Date:  2013-11       Impact factor: 3.996

9.  Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.

Authors:  Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Daniela Frizon Alfieri; Tamires Flauzino; Josiane Lopes; Wildea Lice de Carvalho Jennings Pereira; Caio de Meleck Proença; Sueli Donizete Borelli; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

10.  Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Authors:  C Ford; A D Goodman; K Johnson; N Kachuck; J W Lindsey; R Lisak; C Luzzio; L Myers; H Panitch; J Preiningerova; A Pruitt; J Rose; H Rus; J Wolinsky
Journal:  Mult Scler       Date:  2010-01-27       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.